NKTR - ネクタ―・セラピュ―ティクス (Nektar Therapeutics)

NKTRのニュース

   Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Director Sells 1,560 Shares of Stock  2020/12/18 09:28:44 Watchlist News
Nektar Therapeutics (NASDAQ:NKTR) Director Curet Myriam sold 1,560 shares of Nektar Therapeutics stock in a transaction on Tuesday, December 15th. The shares were sold at an average price of $17.82, for a total transaction of $27,799.20. Following the transaction, the director now owns 19,240 shares in the company, valued at approximately $342,856.80. The transaction was […]
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Nektar Therapeutics EPS beats by $0.16, beats on revenue (NASDAQ:NKTR)  2020/11/05 21:25:05 Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.61 beats by $0.16. Revenue of $30M (+2.7% Y/Y) beats by $7.18M.Revenue was higher due to the recognit
   Growing M&A momentum drives gains in Rhenman’s flagship healthcare hedge fund  2020/10/12 11:36:37 Hedgeweek
Growing M&A momentum drives gains in Rhenman’s flagship healthcare hedge fund Submitted By Hugh Leask | 12/10/2020 - 12:36pm A pick-up in M&A activity within certain healthcare stocks is helping Stockholm-based global healthcare-focused hedge fund Rhenman & Partners Asset Management generate further gains in its flagship equity strategy. The Rhenman Healthcare Equity Long/Short hedge fund advanced 4.36 per cent in its euro-denominated share class during September, which brought its year-to-date return to more than 8 per cent. The strategy’s SEK class meanwhile grew 6.14 per cent last month, and is now up 7.59 per cent since the start of 2020. The fund – which trades a range of small, medium and large pharmaceuticals, biotechnology, medical technology and service company names – took profits from positions in Immunomedics and Novocure, while the worst contributors were Nektar Therapeutics and MacroGenics. US biotech firm Immunomedics, which specialises in antibody-based drugs for cancer and autoimmune diseases, attracted a takeover bid from Gilead Sciences at a premium of 108 per cent, corresponding to a company valuation of USD21 billion, which sent its share price soaring. “That also affects similar companies, so we got some nice tailwinds from contributions of similar types of companies,” said CIO and founding partner Henrik Rhenman in a recent webcast, who noted that Immunomedics’ appeal was strengthened by the approval of its promising new cancer drug, sacituzumab govitecan.
   This Is What Hedge Funds Bought And Sold In The Second Quarter  2020/08/16 17:00:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In The Second Quarter Tyler Durden Sun, 08/16/2020 - 13:00 In addition to the widely publicized changes in Berkshire Hathaway's portfolio, where as we previously reported Warren Buffett dumped a material amount of his bank holdings in addition to completely selling out of airlines, while making his first ever foray into precious metals with a new $ 563MM stake in Barrick Gold , there were other quite notable changes in hedge fund portfolios during Q2 as disclosed in the barrage of 13Fs filed on Friday. As Bloomberg recaps, the 13F filings show that even more hedge funds leaned in to the stay-at-home trade amid the Covid-19 pandemic. Of note, Home Depot was a top new buy for Balyasny Asset Management, while Pershing Square Capital Management and Adage Capital Partners boosted stakes in Lowe’s. Coatue Management boosted its stakes in Peloton and Zoom Video Communications. Netflix was one notable exception as Appaloosa, D1 Capital Partners and Viking Global Investors cut their stakes.
   Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Director Sells 1,560 Shares of Stock  2020/12/18 09:28:44 Watchlist News
Nektar Therapeutics (NASDAQ:NKTR) Director Curet Myriam sold 1,560 shares of Nektar Therapeutics stock in a transaction on Tuesday, December 15th. The shares were sold at an average price of $17.82, for a total transaction of $27,799.20. Following the transaction, the director now owns 19,240 shares in the company, valued at approximately $342,856.80. The transaction was […]
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Nektar Therapeutics EPS beats by $0.16, beats on revenue (NASDAQ:NKTR)  2020/11/05 21:25:05 Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.61 beats by $0.16. Revenue of $30M (+2.7% Y/Y) beats by $7.18M.Revenue was higher due to the recognit
   Growing M&A momentum drives gains in Rhenman’s flagship healthcare hedge fund  2020/10/12 11:36:37 Hedgeweek
Growing M&A momentum drives gains in Rhenman’s flagship healthcare hedge fund Submitted By Hugh Leask | 12/10/2020 - 12:36pm A pick-up in M&A activity within certain healthcare stocks is helping Stockholm-based global healthcare-focused hedge fund Rhenman & Partners Asset Management generate further gains in its flagship equity strategy. The Rhenman Healthcare Equity Long/Short hedge fund advanced 4.36 per cent in its euro-denominated share class during September, which brought its year-to-date return to more than 8 per cent. The strategy’s SEK class meanwhile grew 6.14 per cent last month, and is now up 7.59 per cent since the start of 2020. The fund – which trades a range of small, medium and large pharmaceuticals, biotechnology, medical technology and service company names – took profits from positions in Immunomedics and Novocure, while the worst contributors were Nektar Therapeutics and MacroGenics. US biotech firm Immunomedics, which specialises in antibody-based drugs for cancer and autoimmune diseases, attracted a takeover bid from Gilead Sciences at a premium of 108 per cent, corresponding to a company valuation of USD21 billion, which sent its share price soaring. “That also affects similar companies, so we got some nice tailwinds from contributions of similar types of companies,” said CIO and founding partner Henrik Rhenman in a recent webcast, who noted that Immunomedics’ appeal was strengthened by the approval of its promising new cancer drug, sacituzumab govitecan.
   This Is What Hedge Funds Bought And Sold In The Second Quarter  2020/08/16 17:00:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In The Second Quarter Tyler Durden Sun, 08/16/2020 - 13:00 In addition to the widely publicized changes in Berkshire Hathaway's portfolio, where as we previously reported Warren Buffett dumped a material amount of his bank holdings in addition to completely selling out of airlines, while making his first ever foray into precious metals with a new $ 563MM stake in Barrick Gold , there were other quite notable changes in hedge fund portfolios during Q2 as disclosed in the barrage of 13Fs filed on Friday. As Bloomberg recaps, the 13F filings show that even more hedge funds leaned in to the stay-at-home trade amid the Covid-19 pandemic. Of note, Home Depot was a top new buy for Balyasny Asset Management, while Pershing Square Capital Management and Adage Capital Partners boosted stakes in Lowe’s. Coatue Management boosted its stakes in Peloton and Zoom Video Communications. Netflix was one notable exception as Appaloosa, D1 Capital Partners and Viking Global Investors cut their stakes.
   Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript | The Motley Fool  2020/05/08 07:31:06 The Motley Fool
NKTR earnings call for the period ending March 31, 2020.
   Cerus Corporation Announces Strategic Organizational Changes  2020/03/02 21:10:00 Benzinga Feeds
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader Cerus Corporation (NASDAQ: CERS ) today announced the promotion of three key leaders within the Company in anticipation of the Company's expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/ Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire) "These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine," said William ‘Obi' Greenman, Cerus' president and chief executive officer. "Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus' recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise.
   Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for  2020/02/20 17:31:41 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know  2020/02/06 22:50:10 Zacks Investment Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
   Nektar Therapeutics Pullback May Be Short-Lived  2020/01/23 16:43:15 Schaeffers Investment Research
Nektar has struggled to gain momentum since its early August sell-off

calendar